The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.
Vor Biopharma, a US-based cancer therapy developer backed by pharmaceutical firms Novartis, Johnson & Johnson and PureTech Health, has gone public in a $177m initial public offering.
The company issued 9.83 million shares – increased from 8.8 million – on the Nasdaq Global Select Market priced at $18.00 each, at the top of the IPO’s $16 to $18 range. Its shares closed at $42.83 yesterday, giving it a market capitalisation of approximately $1.52bn.
Vor is working on cellular therapies…
